Novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Abstract

The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.

1 . A method of inhibiting a cancer stem cell, the method comprising inhibiting at least some Stat3 pathway activity in the cancer stem cell through a Stat3 pathway inhibitor.